Viagra goes pink (finally!): First-of-its-kind cream promises to jump-start arousal in women

Is topical viagra worth trying?
How to Use Scream Cream
Get on the List
HERE IS WHAT SHE SAYS...
MeSH terms
Other Scream Cream Ingredients That Boost Libido

Daré cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements.

Step	Action	Details	Tips
1	Clean the skin surface	Use mild soap and water	Dry thoroughly before application
2	Apply a thin layer	Use a pea-sized amount	Avoid excess use
3	Massage gently into skin	Ensure even distribution	Wait 10 minutes before activity
4	Wash hands afterward	To prevent accidental transfer	Use gloves if sensitive skin

Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “seek,” “should,” “would,” “project,” “target,” “explore” “objective,” “on track,” or the negative version of these words and similar expressions.

Viagra cream's popularity is growing among alternative therapies.
It is often advertised online without regulatory approval.
Users should research product ingredients before use.
Topical application may reduce some systemic side effects.
Temporary side effects include flushing and headache.
Proper technique in application influences effectiveness.
Avoid applying to mucous membranes or broken skin.
Expect some changes in sensation in the applied area.
Do not share or reuse leftover cream.
Discuss potential interactions with healthcare providers.

In this press release, forward-looking statements include, but are not limited to, statements relating to plans and timing for commercial availability of DARE to PLAY™ Sildenafil Cream in states in the U.S., production of the compounded drug product in accordance with cGMP requirements, the ability of the product to enhance genital arousal response in women without systemic effects, the market opportunity for the product, its market position, its impact in women’s sexual health, and its ability to gain market acceptance, and Daré’s plans to seek FDA approval of its sildenafil cream formulation, pending additional development activities. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Daré’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: Daré’s reliance on a Section 503B-registered outsourcing facility, a licensed dispensing pharmacy with an online platform, and other third parties to bring DARE to PLAY™ Sildenafil Cream to market and facilitate access to the product and the risk that those third parties do not perform as expected; difficulties in establishing and sustaining relationships with third-party collaborators; the risk that FDA could stop permitting Section 503B-registered outsourcing facilities to manufacture and fulfill orders for compounded sildenafil products or change the conditions under which sildenafil may be used in compounding or compounded sildenafil products may be distributed; the ability of Daré’s outsourcing facility partner to maintain its registration with the FDA under Section 503B of the Federal Food, Drug, and Cosmetic Act; the timing of establishing, and ability to maintain, state-required licensure or registration to enable fulfillment of prescriptions for DARE to PLAY™ Sildenafil Cream; Daré’s inexperience, as a company, in and lack of infrastructure for commercializing products; the degree of market demand and acceptance for DARE to PLAY™ Sildenafil Cream; competitive product launches; greater than expected costs to bring compounded drug products to market and marketing costs; shifts in consumer spending or behavior; Daré’s ability to raise additional capital when and as needed to execute its business strategy and continue as a going concern; Daré’s dependence on grants and other financial awards from governmental entities and a private foundation; limitations on Daré’s ability to raise additional capital through sales of its common stock or other equity securities due to restrictions under SEC and Nasdaq rules and regulations or contractual limitation; Daré’s ability to retain its licensed rights to develop and commercialize a product or product candidate; Daré’s ability to satisfy the monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents and related intellectual property related to its products and product candidates; Daré’s ability to adequately protect or enforce its, or its licensor’s, intellectual property rights; disputes or other developments concerning Daré’s intellectual property rights; product liability claims; governmental investigations or actions relating to Daré’s products or product candidates or the business activities of Daré, its commercial collaborators or other third parties on which Daré relies; changes in healthcare, pharmaceutical, consumer protection or privacy laws and regulatory policies; increased scrutiny from regulators; Daré’s ability to develop, obtain FDA or foreign regulatory approval for, and commercialize its product candidates and to do so on communicated timelines; failure or delay in starting, completing or conducting clinical trials of a product candidate and the inherent uncertainty of outcomes of clinical trials; the risks that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate and that interim data or results from a particular clinical study do not necessarily predict the final results for that study; the risk that the FDA, other regulatory authorities, members of the scientific or medical communities or investors may not accept or agree with Daré’s interpretation of or conclusions regarding data from clinical studies of its product candidates; the effects of macroeconomic conditions, geopolitical events, and major changes and disruptions in U.S. government policies and operations on Daré’s ability to raise additional capital or on Daré’s operations, financial results and condition, and ability to achieve current plans and objectives; Daré’s ability to maintain compliance with Nasdaq’s continued listing requirements and continue to have its common stock listed on The Nasdaq Capital Market; and cybersecurity incidents or similar events that compromise Daré’s technology systems and/or significantly disrupt Daré’s business or those of third parties on which Daré relies. Daré’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements.

Is topical viagra worth trying?

Daré cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “seek,” “should,” “would,” “project,” “target,” “explore” “objective,” “on track,” or the negative version of these words and similar expressions. In this press release, forward-looking statements include, but are not limited to, statements relating to plans and timing for commercial availability of DARE to PLAY™ Sildenafil Cream in states in the U.S., production of the compounded drug product in accordance with cGMP requirements, the ability of the product to enhance genital arousal response in women without systemic effects, the market opportunity for the product, its market position, its impact in women’s sexual health, and its ability to gain market acceptance, and Daré’s plans to seek FDA approval of its sildenafil cream formulation, pending additional development activities. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Daré’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: Daré’s reliance on a Section 503B-registered outsourcing facility, a licensed dispensing pharmacy with an online platform, and other third parties to bring DARE to PLAY™ Sildenafil Cream to market and facilitate access to the product and the risk that those third parties do not perform as expected; difficulties in establishing and sustaining relationships with third-party collaborators; the risk that FDA could stop permitting Section 503B-registered outsourcing facilities to manufacture and fulfill orders for compounded sildenafil products or change the conditions under which sildenafil may be used in compounding or compounded sildenafil products may be distributed; the ability of Daré’s outsourcing facility partner to maintain its registration with the FDA under Section 503B of the Federal Food, Drug, and Cosmetic Act; the timing of establishing, and ability to maintain, state-required licensure or registration to enable fulfillment of prescriptions for DARE to PLAY™ Sildenafil Cream; Daré’s inexperience, as a company, in and lack of infrastructure for commercializing products; the degree of market demand and acceptance for DARE to PLAY™ Sildenafil Cream; competitive product launches; greater than expected costs to bring compounded drug products to market and marketing costs; shifts in consumer spending or behavior; Daré’s ability to raise additional capital when and as needed to execute its business strategy and continue as a going concern; Daré’s dependence on grants and other financial awards from governmental entities and a private foundation; limitations on Daré’s ability to raise additional capital through sales of its common stock or other equity securities due to restrictions under SEC and Nasdaq rules and regulations or contractual limitation; Daré’s ability to retain its licensed rights to develop and commercialize a product or product candidate; Daré’s ability to satisfy the monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents and related intellectual property related to its products and product candidates; Daré’s ability to adequately protect or enforce its, or its licensor’s, intellectual property rights; disputes or other developments concerning Daré’s intellectual property rights; product liability claims; governmental investigations or actions relating to Daré’s products or product candidates or the business activities of Daré, its commercial collaborators or other third parties on which Daré relies; changes in healthcare, pharmaceutical, consumer protection or privacy laws and regulatory policies; increased scrutiny from regulators; Daré’s ability to develop, obtain FDA or foreign regulatory approval for, and commercialize its product candidates and to do so on communicated timelines; failure or delay in starting, completing or conducting clinical trials of a product candidate and the inherent uncertainty of outcomes of clinical trials; the risks that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate and that interim data or results from a particular clinical study do not necessarily predict the final results for that study; the risk that the FDA, other regulatory authorities, members of the scientific or medical communities or investors may not accept or agree with Daré’s interpretation of or conclusions regarding data from clinical studies of its product candidates; the effects of macroeconomic conditions, geopolitical events, and major changes and disruptions in U.S. government policies and operations on Daré’s ability to raise additional capital or on Daré’s operations, financial results and condition, and ability to achieve current plans and objectives; Daré’s ability to maintain compliance with Nasdaq’s continued listing requirements and continue to have its common stock listed on The Nasdaq Capital Market; and cybersecurity incidents or similar events that compromise Daré’s technology systems and/or significantly disrupt Daré’s business or those of third parties on which Daré relies.

Though you cannot place an order quite yet...

Daré’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Daré’s risks and uncertainties, you are encouraged to review its documents filed with the U.S. Securities and Exchange Commission, including Daré’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. For a detailed description of Daré’s risks and uncertainties, you are encouraged to review its documents filed with the U.S. Securities and Exchange Commission, including Daré’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made.

Product	Dosage	Quantity + Bonus	Price
Viagra Generic	25mg	60 + 4 Pills	71.99€ 68.56€
Viagra Super Active	100mg	90 + 10 Pills	165.61€ 157.72€
Viagra Generic	25mg	90 + 6 Pills	105.03€ 100.03€
Viagra Generic	25mg	180 + 6 Pills	154.93€ 147.55€
Viagra Professional	100mg	20 Pills	71.14€ 67.75€
Viagra Professional	100mg	90 + 2 Pills	207.09€ 197.23€
Viagra Original	100mg	120 + 8 Pills	470.39€ 447.99€
Viagra Generic	200mg	90 + 6 Pills	170.79€ 162.66€
Viagra Generic	50mg	10 Pills	26.87€ 25.59€
Viagra Generic	50mg	270 + 8 Pills	198.48€ 189.03€
Viagra Original	100mg	12 Pills	72.54€ 69.09€
Viagra Generic	100mg	90 + 6 Pills	129.02€ 122.88€
Viagra Professional	100mg	270 + 6 Pills	456.97€ 435.21€
Viagra Super Active	100mg	20 + 4 Pills	48.05€ 45.76€
Viagra Oral Jelly	100mg	110 + 9 Sachets	284.63€ 271.08€

Daré undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. In this article, we provide a hypothesis considering the potential effect of phosphodiesterase 5a inhibitors on cellulite. Cellulite is a significant cosmetic problem for many post-adolescent women. Its pathophysiology is complex and involves the presence of excess subcutaneous fat, the microcirculatory system, lymphatics and the extracellular matrix. Many diverse treatments have been tested to treat cellulite like iontophoresis, ultrasound, thermotherapy, pressotherapy, lymphatic drainage and electrolipophoresis which all enhance skin microcirculation.

How to Use Scream Cream

Real results from real women

There have been several attempts to treat cellulite with drugs, but results were insufficient.

Side Effect	Symptoms	Frequency	Severity
Skin irritation	Redness, itching	Common	Mild
Headache	Mild to moderate headaches	Less common	Moderate
Dizziness	Lightheadedness	Rare	Mild
Allergic reactions	Swelling, rash	Rare	Severe

Phosphodiesterases (PDE) are a superfamily of enzymes degrading adenosine monophosphate (cAMP) and cyclic guanosine monophoshpate (cGMP). Human fat cell lipolysis is mediated by both cAMP- and cGMP-dependent protein kinases. Indeed, high dose sildenafil pretreatment led to increased lipolysis in adipocyte cultures.

Get on the List

Altabas hasn’t made any Viagra cream yet, and stresses that his proposal is “just a hypothesis,” and would need a lot of investigation from pharmaceutical companies, if any are interested. Journal reference: Medical Hypotheses (DOI: 10.1016/j.mehy.2009.01.020) She Can Health offers a low libido treatment that can stimulate blood flow to the intimate region. This treatment can help with low libido, hypoactive sexual desire disorder (HSDD), sexual dysfunction, and arousal disorder in women. When applied topically to the intimate area 30 mins before sexual activity, it may: Unlike other products on the market targeted to address Hypoactive Sexual Desire Disorder (HSDD), She Can Health's low libido treatment cream is made in the pharmacy with ingredients that can relax blood vessels, increase oxygenated blood flow, and heighten sensitivity to a woman's most sensitive parts. Each treatment is custom formulated for the individuals needs based on their treatment profile, if our prescriber deems the treatment is appropriate, the product will be produced in our London based compound pharmacy.

Why is clitoral stimulation for orgasm more important during menopause?

That effect could not be attributed exclusively to either PDE3b or PDE5a inhibition, since sildenafil inhibited about 50% of the PDE3b activity in pretreated adipocytes. Sildenafil has a potential beneficial effect on skin microcirculation, as well as on tissue hypoxia.

HERE IS WHAT SHE SAYS...

Sildenafil has a potential beneficial effect on skin microcirculation, as well as on tissue hypoxia. Transdermal or local route of viagra medicine administration should be considered. It could be the ultimate “dream cream” – moisturiser containing Viagra. But, gentlemen, before you get carried away, be aware that the synthesis of lubricant and the popular erectile dysfunction medicine is not intended as a sex aid; instead it is being proposed for women as a treatment for cellulite. The drug sildenafil, sold most famously under the brand name Viagra, has had mixed success as a drug for women, but Croatian researchers are hoping that incorporating the stuff into a moisturiser could open up a whole new market.

Signalling mechanisms regulating lipolysis

Beneath the skin surface is a layer of fatty tissue that is thicker in women with cellulite than those without. The distinctive “orange peel” dimpling pattern associated with cellulite comes from this fat layer and an irregular layer of collagen beneath the skin. Viagra, say Karmela Altabas and colleagues from the University Hospital “Sisters of Charity” in Zagreb, has two things going for it as an anti-cellulite treatment. First, enzyme inhibitors like sildenafil had been shown to break down fat in test tubes, so it might do the same to fat deposited under the skin. And since Viagra famously boosts blood flow, a moisturiser containing the drug might break down fat and then whisk it away. Transdermal or local route of viagra medicine administration should be considered.

MeSH terms

Estradiol Vaginal Cream

It could be the ultimate “dream cream” – moisturiser containing Viagra. But, gentlemen, before you get carried away, be aware that the synthesis of lubricant and the popular erectile dysfunction medicine is not intended as a sex aid; instead it is being proposed for women as a treatment for cellulite. The drug sildenafil, sold most famously under the brand name Viagra, has had mixed success as a drug for women, but Croatian researchers are hoping that incorporating the stuff into a moisturiser could open up a whole new market. Beneath the skin surface is a layer of fatty tissue that is thicker in women with cellulite than those without.

Viagra cream may be marketed with claims of increased stamina.
It can be part of a broader sexual wellness routine.
Some products include herbal or natural extracts.
Expect varying degrees of success based on individual factors.
Use in combination with foreplay can enhance results.
It is not a substitute for medical treatment of ED.
Some formulations require refrigeration for storage.
Discontinue if adverse reactions happen promptly.
The cream should be used responsibly and ethically.
Do not rely solely on topical products for ED issues.

The distinctive “orange peel” dimpling pattern associated with cellulite comes from this fat layer and an irregular layer of collagen beneath the skin.

Other Scream Cream Ingredients That Boost Libido

Wisp Company Reviews

There have been several attempts to treat cellulite with drugs, but results were insufficient. Phosphodiesterases (PDE) are a superfamily of enzymes degrading adenosine monophosphate (cAMP) and cyclic guanosine monophoshpate (cGMP). Human fat cell lipolysis is mediated by both cAMP- and cGMP-dependent protein kinases. Indeed, high dose sildenafil pretreatment led to increased lipolysis in adipocyte cultures. That effect could not be attributed exclusively to either PDE3b or PDE5a inhibition, since sildenafil inhibited about 50% of the PDE3b activity in pretreated adipocytes. Viagra, say Karmela Altabas and colleagues from the University Hospital “Sisters of Charity” in Zagreb, has two things going for it as an anti-cellulite treatment. First, enzyme inhibitors like sildenafil had been shown to break down fat in test tubes, so it might do the same to fat deposited under the skin. And since Viagra famously boosts blood flow, a moisturiser containing the drug might break down fat and then whisk it away. Altabas hasn’t made any Viagra cream yet, and stresses that his proposal is “just a hypothesis,” and would need a lot of investigation from pharmaceutical companies, if any are interested. Journal reference: Medical Hypotheses (DOI: 10.1016/j.mehy.2009.01.020) She Can Health offers a low libido treatment that can stimulate blood flow to the intimate region.

Viagra cream is part of a broader category of topical ED treatments.
It offers an alternative for men who dislike oral medications.
The product may be flavored or designed to mask medicinal taste.
It can be used with other sexual enhancement products cautiously.
Some users prefer creams for their discreet nature.
Clinical research is ongoing into topical PDE5 inhibitors.
Side effects may include skin rash or allergic reaction.
Realistic expectations are important for satisfaction.
Price varies based on brand, formulation, and availability.
Always purchase from reputable sources to ensure quality.

This treatment can help with low libido, hypoactive sexual desire disorder (HSDD), sexual dysfunction, and arousal disorder in women. When applied topically to the intimate area 30 mins before sexual activity, it may: Unlike other products on the market targeted to address Hypoactive Sexual Desire Disorder (HSDD), She Can Health's low libido treatment cream is made in the pharmacy with ingredients that can relax blood vessels, increase oxygenated blood flow, and heighten sensitivity to a woman's most sensitive parts. Each treatment is custom formulated for the individuals needs based on their treatment profile, if our prescriber deems the treatment is appropriate, the product will be produced in our London based compound pharmacy.